BURNABY, BC, Jan. 9 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V:
WBI) today announces the appointment of Yue Zhao as Chief Financial Officer
(CFO) of the Company, effective immediately. Ms. Yue brings in more than 16
years' financial and accounting experience from private and public companies.
Ms. Yue obtained her Certified General Accountant designation from Canada in
1996 and her M.Sc. in finance from the University of British Columbia in 1998.
Dr. Genhui Chen, CEO of the Company, stated that "we are very pleased to
have Ms. Yue take up the key leadership role at Welichem at this time. Her
extensive experience in finance and accounting and related international
experience in the hi-tech business will be invaluable."
Mr. Samson Mui has resigned as the CFO of the Company for personal
reasons. The Company values Mr. Mui's contribution as the CFO of the Company
for the past few years and wishes him well for his future endeavor.About Welichem Biotech Inc.
---------------------------
Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune diseases and cancer.
ON BEHALF OF THE BOARD
Dr. Tan Xiangdong
ChairmanThe TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. This press release contains forward-looking statements that include
our belief as to the potential of our products. Certain risks and
uncertainties such as our ability to successfully commercialize the products
could cause the Company's actual results to differ materially from those in
the forward-looking statements.
%SEDAR: 00021386E
For further information: Genhui Chen, Tel.: (604) 432-1703, Email:
gchen@welichem.com
